Revenue totaled 0.0 million Danish kroner (1.2).
Operating profit was -3.5 million Danish kroner (-3.6).
Profit after tax was -2.8 million Danish kroner (-2.8).
Earnings per share were -0.15 Danish kroner (-0.16).
Cash flow from operating activities was -3.0 million Danish kroner (-5.5).
Cash and cash equivalents totaled 2.3 million Danish kroner (15.1).
During the second quarter, Cessatech continued to develop its strategy and expanded its pediatric portfolio with CT004, which is being developed together with Rigshospitalet. This was stated by CEO Jes Trygved.
After the quarter, the first commercial batch of CT001 was released in the United States, enabling launch activities with selected hospitals. In Europe, Cessatech and Proveca are moving ahead with a re-examination following the CHMP's negative opinion on KemSu/CT001.
Trygved believes that the U.S. launch of CT001 and the broadened development portfolio put the company in a strong position for the next phase of development.
| Cessatech, Mdkk | Q2-2026 | Q2-2025 | Change |
| Net revenue | 0,0 | 1,2 | |
| Operating profit | -3,5 | -3,6 | |
| Net profit | -2,8 | -2,8 | |
| Earnings per share, dkk | -0,15 | -0,16 | |
| Cash flow from operating activities | -3,0 | -5,5 | |
| Cash and cash equivalents | 2,3 | 15,1 | -84,8% |
